Barclays analyst Etzer Darout assumed coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $3.50 price target The firm sees a positive risk/reward for the company’s lead clinical program CX-2051. CytomX’s cash runway will get it through the 2026 data catalysts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics initiated with an Overweight at Barclays
- Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
- CytomX trial ongoing despite grade five event, says Oppenheimer
- CytomX Therapeutics Updates on CX-2051 Phase 1 Study
- CytomX Therapeutics provides update on CX-2051 Phase 1 study